ID   SGOL1_HUMAN             Reviewed;         561 AA.
AC   Q5FBB7; Q588H5; Q5FBB4; Q5FBB5; Q5FBB6; Q5FBB8; Q8N579; Q8WVL0;
AC   Q9BVA8; Q9H275;
DT   10-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   15-MAR-2005, sequence version 1.
DT   22-JUL-2015, entry version 108.
DE   RecName: Full=Shugoshin-like 1;
DE            Short=hSgo1;
DE   AltName: Full=Serologically defined breast cancer antigen NY-BR-85;
GN   Name=SGOL1; Synonyms=SGO1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 4; 5; 6 AND 7),
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15737064; DOI=10.1371/journal.pbio.0030086;
RA   McGuinness B.E., Hirota T., Kudo N.R., Peters J.-M., Nasmyth K.;
RT   "Shugoshin prevents dissociation of cohesin from centromeres during
RT   mitosis in vertebrate cells.";
RL   PLoS Biol. 3:433-449(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 4; 5 AND 6).
RA   Suzuki H., Akiyama N., Tsuji M., Saito S., Eto Y.;
RT   "Human SgoL1 inhibits precocious separation of sister centromere in
RT   early mitosis.";
RL   Submitted (AUG-2004) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 25-561 (ISOFORM 6).
RC   TISSUE=Cervix, Lung, and Mammary gland;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 250-527 (ISOFORM 6), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Mammary gland;
RX   PubMed=12747765;
RA   Scanlan M.J., Gout I., Gordon C.M., Williamson B., Stockert E.,
RA   Gure A.O., Jaeger D., Chen Y.-T., Mackay A., O'Hare M.J., Old L.J.;
RT   "Humoral immunity to human breast cancer: antigen definition and
RT   quantitative analysis of mRNA expression.";
RL   Cancer Immun. 1:4-4(2001).
RN   [5]
RP   FUNCTION, SUBCELLULAR LOCATION, AND DEVELOPMENTAL STAGE.
RX   PubMed=15723797; DOI=10.1016/j.cub.2004.12.044;
RA   Kitajima T.S., Hauf S., Ohsugi M., Yamamoto T., Watanabe Y.;
RT   "Human Bub1 defines the persistent cohesion site along the mitotic
RT   chromosome by affecting Shugoshin localization.";
RL   Curr. Biol. 15:353-359(2005).
RN   [6]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15604152; DOI=10.1073/pnas.0408600102;
RA   Tang Z., Sun Y., Harley S.E., Zou H., Yu H.;
RT   "Human Bub1 protects centromeric sister-chromatid cohesion through
RT   Shugoshin during mitosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:18012-18017(2004).
RN   [7]
RP   SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=16582621;
RA   Wang X., Yang Y., Dai W.;
RT   "Differential subcellular localizations of two human Sgo1 isoforms:
RT   implications in regulation of sister chromatid cohesion and
RT   microtubule dynamics.";
RL   Cell Cycle 5:635-640(2006).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH PPP2CA; PPP2R1A AND
RP   PPP2R5C, AND MUTAGENESIS OF ASN-61 AND LYS-492.
RX   PubMed=16580887; DOI=10.1016/j.devcel.2006.03.010;
RA   Tang Z., Shu H., Qi W., Mahmood N.A., Mumby M.C., Yu H.;
RT   "PP2A is required for centromeric localization of Sgo1 and proper
RT   chromosome segregation.";
RL   Dev. Cell 10:575-585(2006).
RN   [9]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH PPP2CA/PPP2CB; PPP2R1B;
RP   PPP2R5A; PPP2R5B; PPP2R5C; PPP2R5D; PPP2R5E; SET; LRRC59; RBM10/RBM5;
RP   RPL10A; RPL28; RPL7; RPL7A AND RPLP1.
RX   PubMed=16541025; DOI=10.1038/nature04663;
RA   Kitajima T.S., Sakuno T., Ishiguro K., Iemura S., Natsume T.,
RA   Kawashima S.A., Watanabe Y.;
RT   "Shugoshin collaborates with protein phosphatase 2A to protect
RT   cohesin.";
RL   Nature 441:46-52(2006).
RN   [10]
RP   FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=17617734;
RA   Pouwels J., Kukkonen A.M., Lan W., Daum J.R., Gorbsky G.J.,
RA   Stukenberg T., Kallio M.J.;
RT   "Shugoshin 1 plays a central role in kinetochore assembly and is
RT   required for kinetochore targeting of Plk1.";
RL   Cell Cycle 6:1579-1585(2007).
RN   [11]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH NEK2, PHOSPHORYLATION
RP   AT SER-14 AND SER-507, AND MUTAGENESIS OF SER-14 AND SER-507.
RX   PubMed=17621308; DOI=10.1038/cr.2007.55;
RA   Fu G., Ding X., Yuan K., Aikhionbare F., Yao J., Cai X., Jiang K.,
RA   Yao X.;
RT   "Phosphorylation of human Sgo1 by NEK2A is essential for chromosome
RT   congression in mitosis.";
RL   Cell Res. 17:608-618(2007).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH PLK1, AND MUTAGENESIS
RP   OF SER-73 AND THR-146.
RX   PubMed=18331714; DOI=10.1016/j.devcel.2007.12.007;
RA   Wang X., Yang Y., Duan Q., Jiang N., Huang Y., Darzynkiewicz Z.,
RA   Dai W.;
RT   "sSgo1, a major splice variant of Sgo1, functions in centriole
RT   cohesion where it is regulated by Plk1.";
RL   Dev. Cell 14:331-341(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-436, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-507, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   UBIQUITINATION, AND DOMAIN KEN BOX AND D-BOX.
RX   PubMed=19015261; DOI=10.1074/jbc.M807083200;
RA   Karamysheva Z., Diaz-Martinez L.A., Crow S.E., Li B., Yu H.;
RT   "Multiple anaphase-promoting complex/cyclosome degrons mediate the
RT   degradation of human Sgo1.";
RL   J. Biol. Chem. 284:1772-1780(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-256 AND SER-507, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-256, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [18]
RP   INVOLVEMENT IN CAID, VARIANT CAID GLU-23, AND CHARACTERIZATION OF
RP   VARIANT CAID GLU-23.
RX   PubMed=25282101; DOI=10.1038/ng.3113;
RG   FORGE Canada Consortium;
RA   Chetaille P., Preuss C., Burkhard S., Cote J.M., Houde C.,
RA   Castilloux J., Piche J., Gosset N., Leclerc S., Wuennemann F.,
RA   Thibeault M., Gagnon C., Galli A., Tuck E., Hickson G.R., El Amine N.,
RA   Boufaied I., Lemyre E., de Santa Barbara P., Faure S., Jonzon A.,
RA   Cameron M., Dietz H.C., Gallo-McFarlane E., Benson D.W., Moreau C.,
RA   Labuda D., Zhan S.H., Shen Y., Jomphe M., Jones S.J., Bakkers J.,
RA   Andelfinger G.;
RT   "Mutations in SGOL1 cause a novel cohesinopathy affecting heart and
RT   gut rhythm.";
RL   Nat. Genet. 46:1245-1249(2014).
CC   -!- FUNCTION: Plays a central role in chromosome cohesion during
CC       mitosis by preventing premature dissociation of cohesin complex
CC       from centromeres after prophase, when most of cohesin complex
CC       dissociates from chromosomes arms. May act by preventing
CC       phosphorylation of the STAG2 subunit of cohesin complex at the
CC       centromere, ensuring cohesin persistence at centromere until
CC       cohesin cleavage by ESPL1/separase at anaphase. Essential for
CC       proper chromosome segregation during mitosis and this function
CC       requires interaction with PPP2R1A. Its phosphorylated form is
CC       necessary for chromosome congression and for the proper attachment
CC       of spindle microtubule to the kinetochore. Necessary for
CC       kinetochore localization of PLK1 and CENPF. May play a role in the
CC       tension sensing mechanism of the spindle-assembly checkpoint by
CC       regulating PLK1 kinetochore affinity. Isoform 3 plays a role in
CC       maintaining centriole cohesion involved in controlling spindle
CC       pole integrity. {ECO:0000269|PubMed:15604152,
CC       ECO:0000269|PubMed:15723797, ECO:0000269|PubMed:15737064,
CC       ECO:0000269|PubMed:16580887, ECO:0000269|PubMed:17617734,
CC       ECO:0000269|PubMed:17621308, ECO:0000269|PubMed:18331714}.
CC   -!- SUBUNIT: Interacts with PPP2CA (or PPP2CB), PPP2R1B, PPP2R5A,
CC       PPP2R5B, PPP2R5C, PPP2R5D, PPP2R5E, SET, LRRC59, RBM10 (or RBM5),
CC       RPL10A, RPL28, RPL7, RPL7A and RPLP1. Interaction with protein
CC       phosphatase 2A occurs most probably through direct binding to the
CC       regulatory B56 subunits: PPP2R1B, PPP2R5A, PPP2R5B, PPP2R5C,
CC       PPP2R5D, PPP2R5E. Interacts with PPP2R1A and NEK2. Isoform 3
CC       interacts with PLK1. {ECO:0000269|PubMed:16541025,
CC       ECO:0000269|PubMed:16580887, ECO:0000269|PubMed:17621308,
CC       ECO:0000269|PubMed:18331714}.
CC   -!- INTERACTION:
CC       Q15172:PPP2R5A; NbExp=3; IntAct=EBI-989069, EBI-641666;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Chromosome, centromere. Chromosome,
CC       centromere, kinetochore. Cytoplasm, cytoskeleton, spindle pole.
CC       Cytoplasm, cytoskeleton, microtubule organizing center,
CC       centrosome. Note=Localizes to the inner centromere throughout
CC       prophase until metaphase and disappears at anaphase. During
CC       prometaphase, it localizes to a single focus, while at metaphase,
CC       it localizes to 2 spots corresponding to the 2 centromeres.
CC       Centromeric localization requires the presence of BUB1 and the
CC       interaction with PPP2R1A. Localizes to the inner kinetochore from
CC       prophase to early metaphase. Colocalizes with NEK2 and SS18L1 at
CC       the kinetochore. Phosphorylation by AUKRB and the presence of BUB1
CC       are required for localization to the kinetochore. Isoform 1
CC       primarily localizes to kinetochores during G2 phase and mitotic
CC       prophase, metaphase, and anaphase and does not appear to be
CC       associated with kinetochores during late mitosis. Isoform 3 is
CC       found at the centrosome in interphase and at spindle poles in
CC       mitosis and its spindle pole localization is PLK1 dependent.
CC       Isoform 3 does not localize to kinetochores during any stages of
CC       the cell cycle.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC       Name=1; Synonyms=1EF, SgoL1-A2;
CC         IsoId=Q5FBB7-1; Sequence=Displayed;
CC       Name=2; Synonyms=1GH, SgoL1-B2;
CC         IsoId=Q5FBB7-2; Sequence=VSP_016792, VSP_016794;
CC       Name=3; Synonyms=1KL, sSGO1, SgoL1-C2;
CC         IsoId=Q5FBB7-3; Sequence=VSP_016790, VSP_016791;
CC       Name=4; Synonyms=1CD, SgoL1-B1;
CC         IsoId=Q5FBB7-4; Sequence=VSP_016792, VSP_016794, VSP_016795;
CC       Name=5; Synonyms=1AB, SgoL1-C1;
CC         IsoId=Q5FBB7-5; Sequence=VSP_016790, VSP_016791, VSP_016795;
CC       Name=6; Synonyms=1AB, SgoL1-A1;
CC         IsoId=Q5FBB7-6; Sequence=VSP_016795;
CC       Name=7; Synonyms=1J;
CC         IsoId=Q5FBB7-7; Sequence=VSP_016793;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Highly expressed in testis.
CC       Expressed in lung, small intestine, breast, liver and placenta.
CC       Strongly overexpressed in 90% of breast cancers tested.
CC       {ECO:0000269|PubMed:12747765}.
CC   -!- DEVELOPMENTAL STAGE: Appears in prophase cells and remains present
CC       until metaphase. Strongly decreases at the onset of anaphase and
CC       completely disappears at telophase. Not present in interphase
CC       cells (at protein level). {ECO:0000269|PubMed:15723797}.
CC   -!- DOMAIN: The KEN box and D-box 3 are required for its
CC       ubiquitination and degradation. {ECO:0000269|PubMed:19015261}.
CC   -!- PTM: Ubiquitinated and degraded during mitotic exit by APC/C-Cdh1.
CC       {ECO:0000269|PubMed:19015261}.
CC   -!- PTM: Phosphorylation by NEK2 is essential for chromosome
CC       congression in mitosis and for the proper attachment of spindle
CC       microtubule to the kinetochore. Phosphorylated by PLK1 and AUKRB.
CC       {ECO:0000269|PubMed:16582621, ECO:0000269|PubMed:17617734,
CC       ECO:0000269|PubMed:17621308}.
CC   -!- DISEASE: Chronic atrial and intestinal dysrhythmia (CAID)
CC       [MIM:616201]: A disease characterized by dysregulation of the
CC       cardiac sinus node resulting in sick sinus syndrome, in
CC       association with chronic intestinal pseudo-obstruction, a disorder
CC       of gastrointestinal motility in which intestinal obstruction
CC       occurs in the absence of a mechanical obstacle.
CC       {ECO:0000269|PubMed:25282101}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Shugoshin is Japanese for guardian spirit (as it is
CC       known to be a protector of centromeric cohesin).
CC   -!- SIMILARITY: Belongs to the shugoshin family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH01339.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=AAH32696.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB190994; BAD91318.1; -; mRNA.
DR   EMBL; AB193056; BAD95529.1; -; mRNA.
DR   EMBL; AB193057; BAD95530.1; -; mRNA.
DR   EMBL; AB193058; BAD95531.1; -; mRNA.
DR   EMBL; AB193059; BAD95532.1; -; mRNA.
DR   EMBL; AB193060; BAD95533.1; -; mRNA.
DR   EMBL; AB193061; BAD95534.1; -; mRNA.
DR   EMBL; AB193062; BAD95535.1; -; mRNA.
DR   EMBL; AB193063; BAD95536.1; -; mRNA.
DR   EMBL; AB193064; BAD95537.1; -; mRNA.
DR   EMBL; AB193065; BAD95538.1; -; mRNA.
DR   EMBL; AB193066; BAD95539.1; -; mRNA.
DR   EMBL; AB187577; BAD89587.1; -; mRNA.
DR   EMBL; AB187578; BAD89588.1; -; mRNA.
DR   EMBL; AB187579; BAD89589.1; -; mRNA.
DR   EMBL; AB187580; BAD89590.1; -; mRNA.
DR   EMBL; AB187581; BAD89591.1; -; mRNA.
DR   EMBL; AB187582; BAD89592.1; -; mRNA.
DR   EMBL; BC001339; AAH01339.2; ALT_INIT; mRNA.
DR   EMBL; BC017867; AAH17867.1; -; mRNA.
DR   EMBL; BC032696; AAH32696.1; ALT_INIT; mRNA.
DR   EMBL; AF308299; AAG48266.1; -; mRNA.
DR   CCDS; CCDS2635.1; -. [Q5FBB7-3]
DR   CCDS; CCDS33716.1; -. [Q5FBB7-1]
DR   CCDS; CCDS46771.1; -. [Q5FBB7-2]
DR   CCDS; CCDS46772.1; -. [Q5FBB7-5]
DR   CCDS; CCDS46773.1; -. [Q5FBB7-6]
DR   CCDS; CCDS46774.1; -. [Q5FBB7-4]
DR   CCDS; CCDS56243.1; -. [Q5FBB7-7]
DR   RefSeq; NP_001012409.1; NM_001012409.3. [Q5FBB7-6]
DR   RefSeq; NP_001012410.1; NM_001012410.4. [Q5FBB7-1]
DR   RefSeq; NP_001012411.1; NM_001012411.3. [Q5FBB7-4]
DR   RefSeq; NP_001012412.1; NM_001012412.4. [Q5FBB7-2]
DR   RefSeq; NP_001012413.1; NM_001012413.3. [Q5FBB7-5]
DR   RefSeq; NP_001186180.1; NM_001199251.2. [Q5FBB7-6]
DR   RefSeq; NP_001186181.1; NM_001199252.2. [Q5FBB7-1]
DR   RefSeq; NP_001186182.1; NM_001199253.2. [Q5FBB7-4]
DR   RefSeq; NP_001186183.1; NM_001199254.2. [Q5FBB7-2]
DR   RefSeq; NP_001186184.1; NM_001199255.2. [Q5FBB7-5]
DR   RefSeq; NP_001186185.1; NM_001199256.2. [Q5FBB7-3]
DR   RefSeq; NP_001186186.1; NM_001199257.2. [Q5FBB7-7]
DR   RefSeq; NP_612493.1; NM_138484.4. [Q5FBB7-3]
DR   RefSeq; XP_011531675.1; XM_011533373.1. [Q5FBB7-1]
DR   RefSeq; XP_011531676.1; XM_011533374.1. [Q5FBB7-1]
DR   RefSeq; XP_011531677.1; XM_011533375.1. [Q5FBB7-1]
DR   RefSeq; XP_011531678.1; XM_011533376.1. [Q5FBB7-1]
DR   RefSeq; XP_011531679.1; XM_011533377.1. [Q5FBB7-1]
DR   UniGene; Hs.105153; -.
DR   PDB; 3FGA; X-ray; 2.70 A; D=51-96.
DR   PDB; 3Q6S; X-ray; 1.93 A; E/F=445-463.
DR   PDB; 4A0I; X-ray; 2.60 A; C/D=2-6.
DR   PDBsum; 3FGA; -.
DR   PDBsum; 3Q6S; -.
DR   PDBsum; 4A0I; -.
DR   ProteinModelPortal; Q5FBB7; -.
DR   SMR; Q5FBB7; 51-96.
DR   BioGrid; 127395; 13.
DR   DIP; DIP-36614N; -.
DR   IntAct; Q5FBB7; 10.
DR   MINT; MINT-4989914; -.
DR   STRING; 9606.ENSP00000263753; -.
DR   PhosphoSite; Q5FBB7; -.
DR   BioMuta; SGOL1; -.
DR   DMDM; 74741474; -.
DR   MaxQB; Q5FBB7; -.
DR   PaxDb; Q5FBB7; -.
DR   PRIDE; Q5FBB7; -.
DR   Ensembl; ENST00000263753; ENSP00000263753; ENSG00000129810.
DR   Ensembl; ENST00000417364; ENSP00000394613; ENSG00000129810. [Q5FBB7-4]
DR   Ensembl; ENST00000419233; ENSP00000394625; ENSG00000129810. [Q5FBB7-2]
DR   Ensembl; ENST00000421451; ENSP00000414129; ENSG00000129810.
DR   Ensembl; ENST00000425061; ENSP00000414960; ENSG00000129810. [Q5FBB7-2]
DR   Ensembl; ENST00000437051; ENSP00000389034; ENSG00000129810. [Q5FBB7-4]
DR   Ensembl; ENST00000442720; ENSP00000394957; ENSG00000129810. [Q5FBB7-5]
DR   Ensembl; ENST00000443724; ENSP00000413070; ENSG00000129810. [Q5FBB7-7]
DR   GeneID; 151648; -.
DR   KEGG; hsa:151648; -.
DR   UCSC; uc003cbr.3; human. [Q5FBB7-3]
DR   UCSC; uc003cbs.3; human. [Q5FBB7-1]
DR   UCSC; uc003cbt.3; human. [Q5FBB7-2]
DR   UCSC; uc003cbx.3; human. [Q5FBB7-4]
DR   UCSC; uc003cby.3; human. [Q5FBB7-5]
DR   UCSC; uc010hfa.3; human. [Q5FBB7-7]
DR   CTD; 151648; -.
DR   GeneCards; GC03M020179; -.
DR   HGNC; HGNC:25088; SGOL1.
DR   HPA; CAB011569; -.
DR   HPA; HPA035501; -.
DR   MIM; 609168; gene.
DR   MIM; 616201; phenotype.
DR   neXtProt; NX_Q5FBB7; -.
DR   PharmGKB; PA134988556; -.
DR   eggNOG; NOG47262; -.
DR   GeneTree; ENSGT00390000014987; -.
DR   HOVERGEN; HBG080777; -.
DR   InParanoid; Q5FBB7; -.
DR   KO; K11580; -.
DR   OMA; CYYLTCQ; -.
DR   OrthoDB; EOG7FXZZJ; -.
DR   PhylomeDB; Q5FBB7; -.
DR   TreeFam; TF334213; -.
DR   Reactome; REACT_150425; Resolution of Sister Chromatid Cohesion.
DR   Reactome; REACT_150471; Separation of Sister Chromatids.
DR   Reactome; REACT_355252; RHO GTPases Activate Formins.
DR   Reactome; REACT_682; Mitotic Prometaphase.
DR   ChiTaRS; SGOL1; human.
DR   EvolutionaryTrace; Q5FBB7; -.
DR   GeneWiki; SGOL1; -.
DR   GenomeRNAi; 151648; -.
DR   NextBio; 86755; -.
DR   PRO; PR:Q5FBB7; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; Q5FBB7; -.
DR   ExpressionAtlas; Q5FBB7; baseline and differential.
DR   Genevisible; Q5FBB7; HS.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0000775; C:chromosome, centromeric region; IDA:UniProtKB.
DR   GO; GO:0000777; C:condensed chromosome kinetochore; IEA:UniProtKB-SubCell.
DR   GO; GO:0000779; C:condensed chromosome, centromeric region; IDA:UniProtKB.
DR   GO; GO:0000780; C:condensed nuclear chromosome, centromeric region; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0000776; C:kinetochore; IDA:UniProtKB.
DR   GO; GO:0030892; C:mitotic cohesin complex; IDA:MGI.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0000922; C:spindle pole; IDA:UniProtKB.
DR   GO; GO:0019900; F:kinase binding; IDA:MGI.
DR   GO; GO:0008608; P:attachment of spindle microtubules to kinetochore; IDA:UniProtKB.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0010457; P:centriole-centriole cohesion; IDA:UniProtKB.
DR   GO; GO:0007059; P:chromosome segregation; IDA:UniProtKB.
DR   GO; GO:0045132; P:meiotic chromosome segregation; IMP:MGI.
DR   GO; GO:0000278; P:mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0007067; P:mitotic nuclear division; IEA:UniProtKB-KW.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.
DR   InterPro; IPR011515; Shugoshin_C.
DR   InterPro; IPR011516; Shugoshin_N.
DR   Pfam; PF07557; Shugoshin_C; 1.
DR   Pfam; PF07558; Shugoshin_N; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell cycle; Cell division;
KW   Centromere; Chromosome; Chromosome partition; Coiled coil;
KW   Complete proteome; Cytoplasm; Cytoskeleton; Disease mutation;
KW   Kinetochore; Mitosis; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Ubl conjugation.
FT   CHAIN         1    561       Shugoshin-like 1.
FT                                /FTId=PRO_0000055436.
FT   REGION        1    176       Necessary for interaction with PPP2CA and
FT                                PPP2R1A.
FT   COILED        7     89       {ECO:0000255}.
FT   COILED      273    313       {ECO:0000255}.
FT   MOTIF       192    200       D-box 1.
FT   MOTIF       310    312       KEN box.
FT   MOTIF       438    446       D-box 2.
FT   MOTIF       457    465       D-box 3.
FT   MOD_RES      14     14       Phosphoserine; by NEK2.
FT                                {ECO:0000269|PubMed:17621308}.
FT   MOD_RES     256    256       Phosphoserine.
FT                                {ECO:0000269|PubMed:20068231,
FT                                ECO:0000269|PubMed:21406692}.
FT   MOD_RES     436    436       Phosphoserine.
FT                                {ECO:0000269|PubMed:18220336}.
FT   MOD_RES     507    507       Phosphoserine; by NEK2.
FT                                {ECO:0000269|PubMed:17621308,
FT                                ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:20068231}.
FT   VAR_SEQ     159    159       D -> A (in isoform 3 and isoform 5).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:15737064,
FT                                ECO:0000303|Ref.2}.
FT                                /FTId=VSP_016790.
FT   VAR_SEQ     160    428       Missing (in isoform 3 and isoform 5).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:15737064,
FT                                ECO:0000303|Ref.2}.
FT                                /FTId=VSP_016791.
FT   VAR_SEQ     176    176       G -> A (in isoform 2 and isoform 4).
FT                                {ECO:0000303|PubMed:15737064,
FT                                ECO:0000303|Ref.2}.
FT                                /FTId=VSP_016792.
FT   VAR_SEQ     177    522       Missing (in isoform 7).
FT                                {ECO:0000303|PubMed:15737064}.
FT                                /FTId=VSP_016793.
FT   VAR_SEQ     177    428       Missing (in isoform 2 and isoform 4).
FT                                {ECO:0000303|PubMed:15737064,
FT                                ECO:0000303|Ref.2}.
FT                                /FTId=VSP_016794.
FT   VAR_SEQ     522    561       RALEVSPAKEAIFILYYVREFVSRFPDCRKCKLETHICLR
FT                                -> SMKQIQ (in isoform 4, isoform 5 and
FT                                isoform 6). {ECO:0000303|PubMed:12747765,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:15737064,
FT                                ECO:0000303|Ref.2}.
FT                                /FTId=VSP_016795.
FT   VARIANT      23     23       K -> E (in CAID; patient fibroblasts
FT                                exhibit significantly faster cell
FT                                proliferation than controls; during
FT                                mitosis the mutant protein is localized
FT                                in an ordered fashion around the
FT                                centromeres but display a rather
FT                                homogeneous cytoplasmic localization
FT                                pattern). {ECO:0000269|PubMed:25282101}.
FT                                /FTId=VAR_072709.
FT   VARIANT     171    171       V -> A (in dbSNP:rs6806241).
FT                                /FTId=VAR_051968.
FT   VARIANT     322    322       Q -> P (in dbSNP:rs9868701).
FT                                /FTId=VAR_051969.
FT   MUTAGEN      14     14       S->A: Loss of phosphorylation and
FT                                presence of misaligned chromosomes; when
FT                                associated with A-507.
FT                                {ECO:0000269|PubMed:17621308}.
FT   MUTAGEN      61     61       N->I: Loss of interaction with PPP2CA and
FT                                PPP2R1A and loss of centromeric
FT                                localization.
FT                                {ECO:0000269|PubMed:16580887}.
FT   MUTAGEN      73     73       S->A: Loss of proper localization to
FT                                spindle pole and mitotic spindle.
FT                                Significant increase in split spindle
FT                                poles. {ECO:0000269|PubMed:18331714}.
FT   MUTAGEN     146    146       T->A: Loss of proper localization to
FT                                spindle pole and mitotic spindle.
FT                                Significant increase in split spindle
FT                                poles. {ECO:0000269|PubMed:18331714}.
FT   MUTAGEN     492    492       K->A: Loss of centromeric localization.
FT                                {ECO:0000269|PubMed:16580887}.
FT   MUTAGEN     507    507       S->A: Loss of phosphorylation; and
FT                                presence of misaligned chromosomes; when
FT                                associated with A-14.
FT                                {ECO:0000269|PubMed:17621308}.
FT   HELIX        51     93       {ECO:0000244|PDB:3FGA}.
FT   STRAND      448    455       {ECO:0000244|PDB:3Q6S}.
SQ   SEQUENCE   561 AA;  64190 MW;  90CEE0FD2B40CD9C CRC64;
     MAKERCLKKS FQDSLEDIKK RMKEKRNKNL AEIGKRRSFI AAPCQIITNT STLLKNYQDN
     NKMLVLALEN EKSKVKEAQD IILQLRKECY YLTCQLYALK GKLTSQQTVE PAQNQEICSS
     GMDPNSDDSS RNLFVKDLPQ IPLEETELPG QGESFQIEDQ IPTIPQDTLG VDFDSGEAKS
     TDNVLPRTVS VRSSLKKHCN SICQFDSLDD FETSHLAGKS FEFERVGFLD PLVNMHIPEN
     VQHNACQWSK DQVNLSPKLI QPGTFTKTKE DILESKSEQT KSKQRDTQER KREEKRKANR
     RKSKRMSKYK ENKSENKKTV PQKKMHKSVS SNDAYNFNLE EGVHLTPFRQ KVSNDSNREE
     NNESEVSLCE SSGSGDDSDD LYLPTCKYIQ NPTSNSDRPV TRPLAKRALK YTDEKETEGS
     KPTKTPTTTP PETQQSPHLS LKDITNVSLY PVVKIRRLSL SPKKNKASPA VALPKRRCTA
     SVNYKEPTLA SKLRRGDPFT DLCFLNSPIF KQKKDLRRSK KRALEVSPAK EAIFILYYVR
     EFVSRFPDCR KCKLETHICL R
//
